Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

/p>

Study Background

This multicenter, open-label phase I/II study was designed to determine the recommended dose, cardiac safety and antitumor activity of nonpegylated liposomal doxorubicin, paclitaxel and trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) or metastatic breast cancer (MBC).

Sixty-nine adult patients from Spain participated, 15 in the dose escalating part and 54 at the recommended phase II dose. Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC - and a baseline left ventricular ejection fraction (LVEF) > 50 percent - received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and nonpegylated liposomal doxorubicin every three weeks for six cycles. Overall response rate was defined as the total of complete response plus partial response. LVEF was monitored every 3 weeks for the first 18 weeks and every eight weeks thereafter.

Study Results

No case of symptomatic treatment-related cardiac failure was reported. A total of 12 patients (17%) developed asymptomatic minimal and reversible declines in LVEF. In eight of these patients, LVEF recovered to greater than or equal to 50% after a median time of nine weeks (range, 3-38 weeks). In the remaining patients, LVEF ranged from 44% to 49%.

The combination therapy was highly active and well-tolerated. The overall response rate, at the recommended phase II dose, was 98.1%: 29 patients achieved a complete response (53.7%) and 24 patients had a partial response (44.4%). This response rate ranks among the highest reported in HER-2-overexpressing breast cancer patients. The median time to progression was not reached in patients with locally advanced nonoperable breast cancer, while it exceeded 21 months in those with metastatic disease. The most common adverse events included alopecia (85.1%), mucosal inflammati
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... iBridge to Highlight Latest Biomedical Licensing Opportunities , ... KANSAS CITY, Mo. , ... the not-for-profit Kauffman Innovation Network, Inc., today announced that it is ... University Health Network (UHN), a group of leading research hospitals and ...
... XIANYANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- ... a Xianyang-,based manufacturer of a leading over-the-counter Hepatitis B medicine, ... pharmaceutical,products, today announced financial results of the first quarter ended ... Q1 2010 revenue increased 66.0% to $12.4 million, ...
... May 16 Astellas Pharma Inc. (TSE: 4503), a global ... biotechnology company primarily focused on the discovery, development and commercialization of ... today announced that they have entered into a definitive merger agreement ... , , ...
Cached Biology Technology:The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 2Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 3Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 4Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 6
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... the growing mobile commerce market, announces it has retained famous ... the 2015 International CES debut of the Wocket™ biometric smart ... at the NXT-ID booth January 6th and 7 th , ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... North America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated to grow ... the U.S. market holds a larger share in this market, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... the transporter of genetic information within the cell, has ... of the hottest research areas of molecular biology, with ... evolution. But the field is complex, requiring access to ... analysis and bioinformatics, as well as cross-pollination between multiple ...
... announced that James Briscoe of the Medical Research ... the prestigious EMBO Gold Medal for 2008. ... discovery that cells integrate time of exposure and ... graded response. Awarded annually, the EMBO Gold ...
... manipulated cell activity that occurs during the interruption of ... studies. The finding has the potential to become an ... existing drugs might be pressed into service to produce ... is a major problem in many organs, where it ...
Cached Biology News:RNA emerges from DNA's shadow 2RNA emerges from DNA's shadow 3James Briscoe awarded 2008 EMBO Gold Medal 2James Briscoe awarded 2008 EMBO Gold Medal 3Novel approach may protect against heart attack injury 2
Hepatocyte Differentiation Environment...
High voltage electrophoresis power supply...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... has a long and outstanding history ... Several years ago we became aware ... was being modified to inject Xenopus ... redesigning the microdispenser to eliminate any ...
Biology Products: